Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease

Jesper Johannesen; Julie Briody; Mary McQuade; David G Little; Christopher T Cowell; Craig F Munns; Jesper Johannesen; Julie Briody; Mary McQuade; David G Little; Christopher T Cowell; Craig F Munns

doi:10.1016/j.bone.2009.04.255

Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease

Jesper Johannesen, Julie Briody, Mary McQuade, David G Little, Christopher T Cowell, Craig F Munns, Jesper Johannesen, Julie Briody, Mary McQuade, David G Little, Christopher T Cowell, Craig F Munns

31 Citations (Scopus)

Abstract

Background: Intravenous bisphosphonate therapy is associated with preservation of femoral head sphericity and congruence in 77% of children with traumatic avascular necrosis. The aim was to describe the systemic effects of intravenous zoledronic acid (ZA) on bone and mineral metabolism in otherwise normal children and adolescents with femoral head AVN. Material and methods: 37 children (age 10.8+/-2.76 years) diagnosed with avascular necrosis AVN (Slipped Capital Femoral Epiphysis (SCFE), N=20 or Legg-Calve-Perthes disease (LCPD), N=17) were treated with at least 12 months of ZA. Bone mineral density (BMD) by DXA, bone morphometry and mineral homeostasis were evaluated at baseline, 6, 12 and 18 months. Data was retrieved retrospectively. Results: All children maintained height SD during treatment. BMI SD increased in the SCFE subgroup during the first 12 month period. Bone age increased appropriately. Age adjusted total body BMD, lumbar spine BMD and lean tissue mass adjusted bone mineral content (BMC) Z-scores increased significantly over the 18 months of treatment. The LS.BMD increase was greater in LCPD than in SCFE leading to more individuals with LCPD having a LS.BMD((age))Z-score over 2 SD at 12 months follow-up. Biochemical markers of bone turnover were decreased and PTH increased during the first 12 months of treatment and bone modeling was reduced. All markers stabilised over the next 6 months. There were no incidences of fracture, spondylolisthesis or osteonecrosis of the jaw. Conclusion: We here report that ZA in otherwise healthy children with femoral head AVN increases BMD - most pronounced in the LCPD group - and reduces bone modeling and turnover. Further efficacy and safety data are required before this therapy can be widely recommended.

Original language	English
Journal	Bone
Volume	45
Issue number	5
Pages (from-to)	898-902
Number of pages	4
ISSN	8756-3282
DOIs	https://doi.org/10.1016/j.bone.2009.04.255 https://doi.org/10.1016/j.bone.2009.04.255
Publication status	Published - 2009

Access to Document

Cite this

Johannesen, J., Briody, J., McQuade, M., Little, D. G., Cowell, C. T., Munns, C. F., Johannesen, J., Briody, J., McQuade, M., Little, D. G., Cowell, C. T., & Munns, C. F. (2009). Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease. Bone, 45(5), 898-902. https://doi.org/10.1016/j.bone.2009.04.255, https://doi.org/10.1016/j.bone.2009.04.255

Johannesen, J, Briody, J, McQuade, M, Little, DG, Cowell, CT, Munns, CF, Johannesen, J, Briody, J, McQuade, M, Little, DG, Cowell, CT & Munns, CF 2009, 'Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease', Bone, vol. 45, no. 5, pp. 898-902. https://doi.org/10.1016/j.bone.2009.04.255, https://doi.org/10.1016/j.bone.2009.04.255

@article{c28542f0a5f811df928f000ea68e967b,

title = "Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease",

abstract = "Background: Intravenous bisphosphonate therapy is associated with preservation of femoral head sphericity and congruence in 77% of children with traumatic avascular necrosis. The aim was to describe the systemic effects of intravenous zoledronic acid (ZA) on bone and mineral metabolism in otherwise normal children and adolescents with femoral head AVN. Material and methods: 37 children (age 10.8+/-2.76 years) diagnosed with avascular necrosis AVN (Slipped Capital Femoral Epiphysis (SCFE), N=20 or Legg-Calve-Perthes disease (LCPD), N=17) were treated with at least 12 months of ZA. Bone mineral density (BMD) by DXA, bone morphometry and mineral homeostasis were evaluated at baseline, 6, 12 and 18 months. Data was retrieved retrospectively. Results: All children maintained height SD during treatment. BMI SD increased in the SCFE subgroup during the first 12 month period. Bone age increased appropriately. Age adjusted total body BMD, lumbar spine BMD and lean tissue mass adjusted bone mineral content (BMC) Z-scores increased significantly over the 18 months of treatment. The LS.BMD increase was greater in LCPD than in SCFE leading to more individuals with LCPD having a LS.BMD((age))Z-score over 2 SD at 12 months follow-up. Biochemical markers of bone turnover were decreased and PTH increased during the first 12 months of treatment and bone modeling was reduced. All markers stabilised over the next 6 months. There were no incidences of fracture, spondylolisthesis or osteonecrosis of the jaw. Conclusion: We here report that ZA in otherwise healthy children with femoral head AVN increases BMD - most pronounced in the LCPD group - and reduces bone modeling and turnover. Further efficacy and safety data are required before this therapy can be widely recommended.",

author = "Jesper Johannesen and Julie Briody and Mary McQuade and Little, {David G} and Cowell, {Christopher T} and Munns, {Craig F} and Jesper Johannesen and Julie Briody and Mary McQuade and Little, {David G} and Cowell, {Christopher T} and Munns, {Craig F}",

note = "Keywords: Absorptiometry, Photon; Body Height; Body Mass Index; Body Weight; Bone Density Conservation Agents; Child; Cohort Studies; Densitometry; Diphosphonates; Epiphyses; Female; Humans; Imidazoles; Legg-Perthes Disease; Male; Retrospective Studies; Wounds and Injuries",

year = "2009",

doi = "10.1016/j.bone.2009.04.255",

language = "English",

volume = "45",

pages = "898--902",

journal = "Bone",

issn = "8756-3282",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease

AU - Johannesen, Jesper

AU - Briody, Julie

AU - McQuade, Mary

AU - Little, David G

AU - Cowell, Christopher T

AU - Munns, Craig F

AU - Johannesen, Jesper

AU - Briody, Julie

AU - McQuade, Mary

AU - Little, David G

AU - Cowell, Christopher T

AU - Munns, Craig F

N1 - Keywords: Absorptiometry, Photon; Body Height; Body Mass Index; Body Weight; Bone Density Conservation Agents; Child; Cohort Studies; Densitometry; Diphosphonates; Epiphyses; Female; Humans; Imidazoles; Legg-Perthes Disease; Male; Retrospective Studies; Wounds and Injuries

PY - 2009

Y1 - 2009

N2 - Background: Intravenous bisphosphonate therapy is associated with preservation of femoral head sphericity and congruence in 77% of children with traumatic avascular necrosis. The aim was to describe the systemic effects of intravenous zoledronic acid (ZA) on bone and mineral metabolism in otherwise normal children and adolescents with femoral head AVN. Material and methods: 37 children (age 10.8+/-2.76 years) diagnosed with avascular necrosis AVN (Slipped Capital Femoral Epiphysis (SCFE), N=20 or Legg-Calve-Perthes disease (LCPD), N=17) were treated with at least 12 months of ZA. Bone mineral density (BMD) by DXA, bone morphometry and mineral homeostasis were evaluated at baseline, 6, 12 and 18 months. Data was retrieved retrospectively. Results: All children maintained height SD during treatment. BMI SD increased in the SCFE subgroup during the first 12 month period. Bone age increased appropriately. Age adjusted total body BMD, lumbar spine BMD and lean tissue mass adjusted bone mineral content (BMC) Z-scores increased significantly over the 18 months of treatment. The LS.BMD increase was greater in LCPD than in SCFE leading to more individuals with LCPD having a LS.BMD((age))Z-score over 2 SD at 12 months follow-up. Biochemical markers of bone turnover were decreased and PTH increased during the first 12 months of treatment and bone modeling was reduced. All markers stabilised over the next 6 months. There were no incidences of fracture, spondylolisthesis or osteonecrosis of the jaw. Conclusion: We here report that ZA in otherwise healthy children with femoral head AVN increases BMD - most pronounced in the LCPD group - and reduces bone modeling and turnover. Further efficacy and safety data are required before this therapy can be widely recommended.

AB - Background: Intravenous bisphosphonate therapy is associated with preservation of femoral head sphericity and congruence in 77% of children with traumatic avascular necrosis. The aim was to describe the systemic effects of intravenous zoledronic acid (ZA) on bone and mineral metabolism in otherwise normal children and adolescents with femoral head AVN. Material and methods: 37 children (age 10.8+/-2.76 years) diagnosed with avascular necrosis AVN (Slipped Capital Femoral Epiphysis (SCFE), N=20 or Legg-Calve-Perthes disease (LCPD), N=17) were treated with at least 12 months of ZA. Bone mineral density (BMD) by DXA, bone morphometry and mineral homeostasis were evaluated at baseline, 6, 12 and 18 months. Data was retrieved retrospectively. Results: All children maintained height SD during treatment. BMI SD increased in the SCFE subgroup during the first 12 month period. Bone age increased appropriately. Age adjusted total body BMD, lumbar spine BMD and lean tissue mass adjusted bone mineral content (BMC) Z-scores increased significantly over the 18 months of treatment. The LS.BMD increase was greater in LCPD than in SCFE leading to more individuals with LCPD having a LS.BMD((age))Z-score over 2 SD at 12 months follow-up. Biochemical markers of bone turnover were decreased and PTH increased during the first 12 months of treatment and bone modeling was reduced. All markers stabilised over the next 6 months. There were no incidences of fracture, spondylolisthesis or osteonecrosis of the jaw. Conclusion: We here report that ZA in otherwise healthy children with femoral head AVN increases BMD - most pronounced in the LCPD group - and reduces bone modeling and turnover. Further efficacy and safety data are required before this therapy can be widely recommended.

U2 - 10.1016/j.bone.2009.04.255

DO - 10.1016/j.bone.2009.04.255

M3 - Journal article

C2 - 19446052

SN - 8756-3282

VL - 45

SP - 898

EP - 902

JO - Bone

JF - Bone

IS - 5

ER -

Systemic effects of zoledronic acid in children with traumatic femoral head avascular necrosis and Legg-Calve-Perthes disease

Abstract

Access to Document

Fingerprint

Cite this